All articles by Andrew Hillman
Andrew Hillman is a data journalist at GlobalData Media, specialising in healthcare and pharmaceutical coverage. He is a graduate of Birmingham City University's data journalism program and previously worked as an analyst and modeller in the emergency healthcare sector.
Andrew Hillman
@ajhillman_ddj
Decentralised paediatric clinical trials trending up but study execution critical
DCT Adoption Tracker: Clinical Trials Arena investigates which paediatric disease spaces are using decentralisation the most and why.
Beyond clinical trial design: factors that impact decentralisation
DCT Adoption Tracker: Clear regulatory guidance, existing healthcare infrastructure, and local culture are key influencers for swift decentralisation uptake.
Women’s health clinical trials: breaking down barriers through decentralisation
Women tend to be harder to recruit for clinical trials due to socioeconomic factors. But decentralised study designs help ease barriers to participation.
The great wall: why overseas sponsors are yet to fully tap into China’s clinical trial resources
China is an attractive study destination, yet our data-driven analysis shows the country’s clinical trial industry is still insular. Clinical Trials Arena maps the barricades.
DCT Adoption Tracker: Top 3 clinical trial decentralisation trends in Q1 2022
Clinical Trials Arena updates its exclusive taxonomic review of decentralised clinical trials with a spotlight on notable shifts in the past quarter.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Covid-19 two years on: persistent symptoms of clinical trial disruption trouble certain therapy areas
In an exclusive analysis using GlobalData and ClinicalTrials.gov data, Clinical Trials Arena reveals which therapeutic areas are recuperating and which are struggling to recover past levels of trial activity.
Who and what is at the crest of the clinical trial decentralisation wave?
DCT Adoption Tracker: In an exclusive analysis, Clinical Trials Arena combed through drug trial public information to find out which decentralised approaches are making waves and talked to experts to put trends into context.
Trial Activity Snapshot: Did Australia’s “zero-Covid” plan protect clinical trial activity?
In an exclusive, Clinical Trials Arena dives into Australia’s trial activity data to find out how the pandemic impacted the country’s trial action.
Filings buzz in pharma: 92% increase in internet of things mentions in Q2
Frequency of sentences related to the internet of things between July 2020 and June 2021 was 350% higher than in 2016.
2022 forecast: diabetes, cardiovascular, respiratory trial activity set to rebound
Trial activity is on course to recuperate in hypertension, respiratory tract infections next year.